Teva Pharmaceutical Indus Financials - Benzinga

Teva Pharmaceutical Industries Ltd

TEVANYSE

Trade with Public

Trade with Public

$36.93

-0.41-1.1%

At close: Aug 21, 5:00 PM EST

$37.37

0.030.08%

Pre-Market: 8:52 AM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Teva Pharmaceutical Indus Financials

Teva Pharmaceutical Indus (TEVA) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Teva's Innovative Drug Portfolio Fuels Growth as Company Raises Outlook, Transitions to Direct NYSE Listing

Teva revenue tops estimates despite an earnings miss. The company raises 2026 sales guidance and highlights strong brand growth.

Vandana Singh

PRO
Teva Pharmaceutical Indus Lowers FY2026 Adj EPS Guidance from $2.57-$2.77 to $1.91-$2.11 vs $2.04 Est; Raises FY2026 Sales Guidance from $16.400B-$16.800B to $16.500B-$16.850B vs $16.618B Est

Teva Pharmaceutical Indus (NYSE:TEVA) lowers FY2026 Adj EPS guidance from $2.57-$2.77 to $1.91-$2.11 vs $2.04 analyst estimate. Raises FY2026 sales outlook from $16.400 billion-$16.800 billion to $16.500 billion-$16.850

Benzinga Newsdesk

PRO
Teva Pharmaceutical Indus Q2 Adj. EPS $0.02 Misses $0.25 Estimate, Sales $4.142B Beat $4.047B Estimate

Teva Pharmaceutical Indus (NYSE:TEVA) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.25 by 92 percent. This is a 96.97 percent decrease over earnings of $0.66 per share

Benzinga Newsdesk

Teva Signals Confidence With $700 Million Pipeline Push, Buyback Plan

Teva to acquire Emalex for $700 million, posts Q1 earnings beat, and maintains 2026 outlook amid margin and buyback plans.

Vandana Singh

Earnings Scheduled For April 29, 2026

Benzinga Insights

PRO
Teva Pharmaceutical Indus Affirms FY2026 Adj EPS Guidance of $2.57-$2.77 vs $2.67 Est; Affirms FY2026 Sales Guidance of $16.400B-$16.800B vs $16.570B Est

Teva Pharmaceutical Indus (NYSE:TEVA) affirms FY2026 Adj EPS guidance from $2.57-$2.77 to $2.57-$2.77 vs $2.67 analyst estimate. Affirms FY2026 sales outlook from $16.400 billion-$16.800 billion to $16.400

Benzinga Newsdesk